Phio Pharmaceuticals Corp. (PHIO)

Market Cap	1.86M
Revenue (ttm)	n/a
Net Income (ttm)	-7.42M
Shares Out	1.06M
EPS (ttm)	-12.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	344,356
Open	1.650
Previous Close	1.740
Day's Range	1.570 - 1.810
52-Week Range	1.530 - 10.350
Beta	1.46
Analysts	Strong Buy
Price Target	36.00 (+1,945.46%)
Earnings Date	Nov 14, 2024

About PHIO

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enab...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: PHIO
• Website: https://phiopharma.com

Analyst Forecast

According to one analyst, the rating for PHIO stock is "Strong Buy" and the 12-month stock price forecast is $36.0.

Price Target

$36.0

(1,945.46% upside)

Analyst Consensus: Strong Buy